Core Points - The stock of Xinmai Medical (688016) closed at 100.0 yuan on October 30, 2025, down 5.14% from the previous trading day, with a total market capitalization of 12.326 billion yuan [1] - The company reported a revenue of 1,014,780,041.62 yuan for the first three quarters of 2025, representing a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429,055,896.79 yuan [1] - Research and development (R&D) expenses totaled 89,097,024.52 yuan, down 31.60% year-on-year, due to the optimization of the R&D team structure and project commercialization potential assessment [1] - As of September 30, 2025, the company repurchased 1,263,043 shares, accounting for 1.02% of the total share capital, with a total expenditure of 132,745,761.84 yuan [1] - The total assets of the company reached 4,732,362,656.89 yuan, an increase of 10.27% compared to the end of the previous year, while the equity attributable to shareholders grew by 4.35% to 3,956,811,416.72 yuan [1]

Core Points - On October 30, Xinmai Medical experienced a decline of 5.03%, trading at 100.12 CNY per share, with a transaction volume of 375 million CNY and a turnover rate of 3.00%, resulting in a total market capitalization of 12.341 billion CNY [1] Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. was established on August 17, 2012, and went public on July 22, 2019. The company specializes in the research, development, production, and sales of interventional medical devices for aortic and peripheral blood vessels [1] - The revenue composition of the company is as follows: 71.94% from aortic products, 28.04% from peripheral and other products, and 0.02% from other supplementary sources [1] Shareholder Information - Among the top ten circulating shareholders of Xinmai Medical, a fund under Huabao Fund holds a significant position. The Huabao CSI Medical ETF (512170) reduced its holdings by 301,200 shares in the third quarter, now holding 2.115 million shares, which accounts for 1.72% of the circulating shares [2] - The Huabao CSI Medical ETF (512170) was established on May 20, 2019, with a latest scale of 26.404 billion CNY. Year-to-date, it has achieved a return of 15%, ranking 3359 out of 4216 in its category; over the past year, it has returned 8.02%, ranking 3532 out of 3885; and since inception, it has returned 12.69% [2] - The fund manager of Huabao CSI Medical ETF is Hu Jie, who has a tenure of 13 years and 18 days, managing total assets of 100.204 billion CNY. During his tenure, the best fund return was 180.89%, while the worst was -98.01% [2]

Group 1 - Core viewpoint: Xinmai Medical (688016.SH) reported its Q3 2025 results, highlighting significant institutional investor interest with 20 institutions holding a total of 58.3275 million shares, representing 47.32% of the total share capital [1] - The top ten institutional investors collectively hold 47.20% of the shares, with a 0.59 percentage point increase from the previous quarter [1] - Major institutional investors include MicroPort Endovascular CHINA Corp. Limited and Hong Kong Central Clearing Limited among others [1] Group 2 - In the public fund sector, one fund, Xinhua Strategic Emerging Industries Flexible Allocation Mixed Fund, increased its holdings, while two funds, Huabao CSI Medical ETF and Southern CSI 1000 ETF, reduced their holdings by 0.26% [2] - Nine new public funds were disclosed this period, including Guotai Junan Multi-Strategy Flexible Allocation Mixed A and others [2] - A total of 184 public funds were not disclosed this period, including notable funds like Bosera Sci-Tech 100 ETF and others [2] Group 3 - From the foreign investment perspective, one new foreign institution, Hong Kong Central Clearing Limited, was disclosed this period [3]

Core Insights - The company reported a revenue of 1.015 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 4.66% [1] - The net profit attributable to the company was 429 million yuan, showing a year-on-year decline of 22.46% [1] Financial Performance - Revenue for the first three quarters: 1.015 billion yuan, up 4.66% year-on-year [1] - Net profit for the same period: 429 million yuan, down 22.46% year-on-year [1]

Core Viewpoint - MicroPort Medical (00853) reported the performance of its subsidiary, HeartCare Medical (688016.SH), for the first three quarters of 2025, indicating a mixed financial outcome with revenue growth but a decline in net profit [1] Financial Performance - Revenue for the first three quarters was approximately 1.015 billion yuan, representing a year-on-year increase of 4.66% [1] - Net profit attributable to shareholders was around 429 million yuan, showing a year-on-year decrease of 22.46% [1] - Basic earnings per share stood at 3.54 yuan [1]

Group 1 - The core point of the article is that MicroPort Medical (00853) reported the performance of its subsidiary, HeartCare Medical (688016.SH), for the first three quarters of 2025, showing a revenue of approximately 1.015 billion yuan, which represents a year-on-year growth of 4.66% [1] - The net profit attributable to shareholders of the listed company is approximately 429 million yuan, reflecting a year-on-year decrease of 22.46% [1] - The basic earnings per share are reported at 3.54 yuan [1]

Group 1 - The core point of the article is that Xinmai Medical reported its Q3 performance, showing a revenue increase but a significant decline in net profit [1] Group 2 - Xinmai Medical's revenue for the first three quarters of 2025 is approximately 1.015 billion yuan, representing a year-on-year increase of 4.66% [1] - The net profit attributable to shareholders for the same period is about 429 million yuan, reflecting a year-on-year decrease of 22.46% [1] - As of the report date, Xinmai Medical's market capitalization stands at 13 billion yuan [2]

证券代码：688016 证券简称：心脉医疗 公告编号：2025-044 上海微创心脉医疗科技（集团）股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 召开日期时间：2025 年 11 月 14 日 14 点 00 分 召开地点：上海市浦东新区康新公路 3399 弄 1 号楼 1 层公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 14 日 至2025 年 11 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年11月14日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） ...

Revenue and Profit - The company's revenue for Q3 2025 reached ¥300,350,261.64, representing a year-over-year increase of 64.68%[4] - Total profit for the period was ¥130,607,340.82, a decrease of 20.88% compared to the same period last year[4] - Net profit attributable to shareholders was ¥114,408,672.85, down 23.63% year-over-year[4] - Total operating revenue for the first three quarters of 2025 reached ¥1,014,780,041.62, an increase from ¥969,564,236.70 in the same period of 2024, representing a growth of approximately 4.3%[19] - Operating profit for the first three quarters of 2025 was ¥497,462,954.23, compared to ¥637,790,237.07 in 2024, reflecting a decrease of approximately 22.0%[20] - Net profit for the first three quarters of 2025 was ¥423,065,173.14, down from ¥547,177,167.51 in 2024, a decline of about 22.7%[20] - Basic earnings per share for the first three quarters of 2025 were ¥3.54, compared to ¥4.49 in the same period of 2024, a decrease of approximately 21.2%[21] Expenses and Costs - Research and development expenses totaled ¥25,851,086.52, a decrease of 28.12% compared to the same period last year[5] - Total operating costs for the first three quarters of 2025 were ¥563,934,629.28, up from ¥443,293,120.87 in 2024, indicating an increase of about 27.3%[20] - The company paid CNY 43,558,034.80 in dividends and interest in the first three quarters of 2025, a decrease from CNY 248,178,759.00 in the same period of 2024, reflecting a reduction of about 82.5%[25] Assets and Liabilities - The total assets of the company increased by 10.27% year-over-year, reaching ¥4,732,362,656.89[5] - Total assets increased to ¥4,732,362,656.89 in 2025 from ¥4,291,597,451.31 in 2024, marking a growth of about 10.3%[16] - Total liabilities rose to ¥750,072,716.20 in 2025, compared to ¥469,125,424.12 in 2024, an increase of approximately 59.9%[16] - Non-current liabilities totaled ¥135,054,880.90 in 2025, slightly up from ¥130,086,642.62 in 2024, indicating a growth of about 3.7%[16] - The company's total equity increased to ¥3,982,289,940.69 in 2025 from ¥3,822,472,027.19 in 2024, reflecting a growth of approximately 4.2%[16] Cash Flow - The company reported a cash flow from operating activities of ¥363,201,648.36, a decrease of 3.26% year-over-year[4] - In the first three quarters of 2025, the net cash flow from operating activities was CNY 363,201,648.36, compared to CNY 375,446,862.07 in the same period of 2024, reflecting a decrease of approximately 2.9%[24] - Total cash inflow from investment activities in the first three quarters of 2025 was CNY 2,934,168,253.08, while cash outflow was CNY 4,305,020,875.92, resulting in a net cash flow of -CNY 1,370,852,622.84[25] - The total cash outflow for operating activities in the first three quarters of 2025 was CNY 598,595,046.84, compared to CNY 651,367,599.52 in 2024, indicating a decrease of about 8.1%[24] - The company's cash inflow from financing activities was CNY 126,000,000.00 in the first three quarters of 2025, compared to CNY 35,000,000.00 in the same period of 2024, marking an increase of approximately 260%[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,990[11] - MicroPort Endovascular holds 39.77% of shares, totaling 49,025,370 shares[11] - The company has repurchased a total of 1,263,043 shares, accounting for 1.02% of total share capital, with a total expenditure of RMB 132,745,761.84[13] - The second phase of the share repurchase plan has been completed as of the report date[13] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[12] Operational Insights - The company aims to optimize its R&D team structure and improve the output ratio of R&D investments, leading to a reduction in R&D spending[9] - The company continues to expand its overseas market presence, enhancing product competitiveness and steadily increasing production and sales volumes[9] - The company has not identified any other significant operational issues during the reporting period[13] - The cash flow from operating activities showed a slight increase in 2025 compared to 2024, indicating stable operational performance despite challenges in sales revenue[24] - The company is not applying new accounting standards or interpretations for the first time in 2025, maintaining consistency in financial reporting[26]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《心脉医疗：关于第二期股份回购实施结果暨股份变动的公告》 公司近日发布公告称，关于第二期股份回购实施结果暨股份变动情况如下：证券代码：688016，证券简 称：心脉医疗。公司于2024年10月28日至2025年10月27日期间实施第二期股份回购，回购价格上限为 176.73元/股，预计回购金额10,000万元至20,000万元。截至2025年10月27日，公司以集中竞价交易方式 累计回购股份1,333,943股，占公司总股本的1.08%，回购价格区间为84.26元/股至120元/股，支付资金总 额140,098,144.06元（不含交易费用）。本次回购符合董事会审议通过的方案，资金来源为自有资金和 股票回购专项贷款。回购股份将全部用于员工持股计划或股权激励，并在公告披露后3年内使用完毕， 未使用部分将依法注销。回购后公司股权分布仍符合上市条件。 最新公告列表 截至2025年10月29日收盘，心脉医疗（688016）报收于105.42元，较前一交易日上涨1.29%，最新总市 值为129. ...